Brean Capital Reiterates Buy On TG Therapeutics Following TGR-1202 Interim Data Release
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a $22 price target, as the company announced updated clinical results from its ongoing Phase I single agent dose escalation study of TGR-1202, the Company’s oral, once-daily, PI3K delta inhibitor.
Aschoff noted, “We look forward to additional TGR-1202 data and the start of combination therapy Phase 3 in 1H15, likely under an SPA, in our view. Among the 55 patients evaluable for safety, TGR-1202 was well tolerated with no MTD yet identified. Notably, no drug-related liver toxicity or colitis occurred, especially considering the median time on TGR-1202 of 6 months and that some patients have been on TGR-1202 for over 1.5 years. TGR-1202’s benign safety profile shows strong potential for combination therapy.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of 15.2% and a 70.4% success rate. Aschoff has a 18.2% average return when recommending TGTX, and is ranked #85 out of 3398 analysts.